Stock Markets
Tempus AI’s heart monitoring tool gets FDA nod
CHICAGO – Tempus AI, Inc. (NASDAQ: TEM), a technology firm focused on artificial intelligence in healthcare, has obtained 510(k) clearance from the U.S. Food and Drug Administration for its Tempus ECG-AF device. This device employs AI to identify patients at an increased risk of atrial fibrillation/flutter (AF), a common heart condition associated with stroke.
The FDA’s authorization marks the first for an AF indication in the category known as cardiovascular machine learning-based notification software. This development allows healthcare providers to incorporate Tempus’s algorithm into patient care, potentially aiding in the early detection of cardiovascular diseases.
Tempus’s ECG-AF is designed to analyze 12-lead electrocardiogram (ECG) recordings and detect signs that could indicate a patient experiencing AF within the next 12 months. It is intended for patients 65 years or older who do not have a known history of AF. While the device provides results that aid in diagnosis, it is not meant to determine a person’s overall risk of AF and should not be the sole diagnostic tool. Physicians are advised to consider the Tempus ECG-AF results alongside other diagnostic information, including the patient’s original ECG recordings, other tests, symptoms, and clinical history.
Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus, expressed the company’s belief in the importance of early diagnosis and treatment of AF to prevent unnecessary deaths related to the condition. The Tempus ECG-AF is part of a larger suite of diagnostics aimed at identifying various cardiovascular risks.
About Tempus: Tempus is a company that applies AI in healthcare, holding one of the world’s largest libraries of multimodal data. It aims to provide AI-enabled precision medicine solutions to physicians, enhance personalized patient care, and support therapeutic development and delivery.
This clearance is based on a press release statement and represents a significant step for Tempus in its mission to advance precision medicine. However, the company also cautions about forward-looking statements within the release, which involve risks and uncertainties that could affect Tempus’s business and financial performance.
InvestingPro Insights
As Tempus AI, Inc. (NASDAQ: TEM) makes strides in the healthcare technology sector with its recent FDA clearance for the Tempus ECG-AF device, the company’s financial health and stock performance are critical for investors to consider. According to InvestingPro data, Tempus has a market capitalization of $4.11 billion, indicative of its substantial presence in the industry. However, it’s worth noting that the company’s stock has seen a significant downturn over the past week, with a one-week price total return of -17.71%, and this trend has persisted over the last month, with a one-month price total return of -37.99%.
Despite these challenges in the stock market, the company’s revenue growth remains robust, with a quarterly increase of 26.12% as of Q1 2024. This suggests that Tempus’s business operations are expanding, potentially due to increased interest and investment in AI-driven healthcare solutions. Nevertheless, it’s important to recognize that the company is not currently profitable, with an operating income margin of -34.82% and a negative P/E ratio of -13.67, reflecting the difficulties often faced by growth-oriented tech companies in balancing investment with immediate profitability.
Investors should also be aware that Tempus operates with a moderate level of debt and does not pay dividends, which could be a consideration for those seeking income-generating investments. The InvestingPro Tips indicate that while the stock has been under pressure recently, there are 5 additional tips available on InvestingPro that could provide further insights into the company’s financials and stock performance. For those interested in a deeper analysis, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at https://www.investing.com/pro/TEM.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
By Maggie Fick and Ahmed Aboulenein
WASHINGTON (Reuters) – Members of Donald Trump’s presidential transition team are laying the groundwork for the United States to withdraw from the World Health Organization on the first day of his second term, according to a health law expert familiar with the discussions.
“I have it on good authority that he plans to withdraw, probably on Day One or very early in his administration,” said Lawrence Gostin, professor of global health at Georgetown University in Washington and director of the WHO Collaborating Center on National and Global Health (NS:) Law.
The Financial Times was first to report on the plans, citing two experts. The second expert, former White House COVID-19 response coordinator Ashish Jha, was not immediately available for comment.
The Trump transition team did not immediately respond to a Reuters request for comment.
The plan, which aligns with Trump’s longstanding criticism of the U.N. health agency, would mark a dramatic shift in U.S. global health policy and further isolate Washington from international efforts to battle pandemics.
Trump has nominated several critics of the organization to top public health positions, including Robert F. Kennedy Jr., a vaccine skeptic who is up for the post of secretary of Health and Human Services, which oversees all major U.S. health agencies including the CDC and FDA.
Trump initiated the year-long withdrawal process from the WHO in 2020 but six months later his successor, President Joe Biden, reversed the decision.
Trump has argued that the agency failed to hold China accountable for the early spread of COVID-19. He has repeatedly called the WHO a puppet of Beijing and vowed to redirect U.S. contributions to domestic health initiatives.
A WHO spokesperson declined to directly comment but referred Reuters to comments by WHO Director-General Tedros Adhanom Ghebreyesus at a press briefing on Dec. 10 in which he was asked whether he was concerned that the Trump administration would withdraw from the organization.
Tedros said at the time that the WHO needed to give the U.S. time and space for the transition. He also voiced confidence that states could finalize a pandemic agreement by May 2025.
Critics warn that a U.S. withdrawal could undermine global disease surveillance and emergency response systems.
“The U.S. would lose influence and clout in global health and China would fill the vacuum. I can’t imagine a world without a robust WHO. But U.S. withdrawal would severely weaken the agency,” Gostin said.
U.Today – MicroStrategy has made headlines again by purchasing 5,262 BTC for approximately $561 million at an average price of $106,662 per BTC. The company now holds a staggering 444,262 BTC, accumulated at a total cost of approximately $27.7 billion, with an average purchase price of $62,257 per BTC.
Despite impressive returns of 47.4% since the beginning of the quarter and 73.7% since the beginning of the year, skepticism about the company’s strategy is growing.
It is believed that to sustain its purchases, MicroStrategy raises capital through methods such as issuing convertible and corporate bonds, securing credit lines and selling shares.
This cycle appears to operate as follows: shares are sold to acquire the cryptocurrency, and the rising price per BTC increases asset value, enabling further loans, which are then reinvested in more purchases.
Some observers warn that a significant decline in Bitcoin’s price or MicroStrategy’s stock could trigger a cascade effect. A sharp fall in MSTR shares would weaken the collateral backing its loans, potentially leading to forced asset sales, including BTC.
This scenario could exert downward pressure on the broader cryptocurrency market, as the company holds 2.2% of the global Bitcoin supply now.
Thus, while some view Michael Saylor’s approach as a bold bid to cement the cryptocurrency’s role in the financial system, others see it as unsustainable. History offers a cautionary note: in 2000, MSTR shares surged to $333 before plummeting 99%, a collapse that took 24 years to recover from.
National homebuilder ranked No. 12 on inaugural list ranking companies based on trust
SCOTTSDALE, Ariz., Dec. 23, 2024 /PRNewswire/ — With a longstanding reputation for trust, national homebuilder and land developer Taylor Morrison (NYSE:) (NYSE: ™HC) has been recognized by Forbes on their inaugural list of the Most Trusted Companies in America. The homebuilder ranked No. 12 out of 300 companies across all industries.
“There are few things more powerful than trust and it’s something we strive to earn amongst all company stakeholders, from our customers to our team members, our shareholders, and our local communities,” said Taylor Morrison Chairman and CEO Sheryl Palmer. “To be included on this esteemed list in its inaugural year is especially meaningful and these awards are important reminders of the relationships we’re building across all aspects of our business.”
Fueled by hundreds of millions of data points, the Most Trusted Companies in America list combines data on a wide range of factors across four categories: employee trust, customer trust, investor trust and media sentiment. The ranking was created in partnership with research companies HundredX, Signal AI and Glassdoor.
Taylor Morrison also earned the No. 67 spot on Forbes’ inaugural America’s Best Companies list. The ranking is Forbes’ most comprehensive company ranking to date and factored in ratings for financial performance, customer and employee satisfaction, cybersecurity, sustainability, companies’ remote work policies, media coverage and more. Forbes’ America’s Best Companies list assessed more than 60 metrics across 11 primary categories to identify which organizations excel across the board. Of the more than 2,000 U.S.-based publicly traded companies that were eligible, only 300 qualified for each list.
In addition to being named among the Most Trusted and Best Companies in America by Forbes, Taylor Morrison holds several additional accolades including being named on Newsweek’s America’s Most Responsible Companies and America’s Greenest Companies lists, U.S. News & World Report’s Best Companies to Work For list, the American Opportunity (SO:) Index, America’s Most Trusted ® Home Builder for nine years, Hearthstone’s 2021 BUILDER Humanitarian Award, and inclusion on the Fortune 500 list since 2021.
About Taylor Morrison
Headquartered in Scottsdale, Arizona, Taylor Morrison is one of the nation’s leading homebuilders and developers. We serve a wide array of consumers from coast to coast, including first-time, move-up, luxury and resort lifestyle homebuyers and renters under our family of brands”including Taylor Morrison, Esplanade and Yardly. From 2016-2024, Taylor Morrison has been recognized as America’s Most Trusted ® Builder by Lifestory Research. Our long-standing commitment to sustainable operations is highlighted in our annual Sustainability and Belonging Report.
For more information about Taylor Morrison, please visit www.taylormorrison.com.
CONTACT:
media@taylormorrison.com
Forex2 years agoForex Today: the dollar is gaining strength amid gloomy sentiment at the start of the Fed’s week
- Forex2 years ago
How is the Australian dollar doing today?
- Forex2 years ago
Unbiased review of Pocket Option broker
- Forex2 years ago
Dollar to pound sterling exchange rate today: Pound plummeted to its lowest since 1985
- Cryptocurrency2 years ago
What happened in the crypto market – current events today
- World2 years ago
Why are modern video games an art form?
- Commodities2 years ago
Copper continues to fall in price on expectations of lower demand in China
- Forex2 years ago
The dollar is down again against major world currencies
